December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Myeloma Paper of the Day, December 26th, suggested by Robert Orlowski
Dec 26, 2024, 15:03

Myeloma Paper of the Day, December 26th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

“Myeloma Paper of the Day: iStopMM (prospective population-based screening study) shows MGUS associated with increased venous thrombosis risk (HR=1.43; 95% CI: 1.19-1.73) but not arterial thrombosis risk; M protein concentration not assoc. with either.

Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population-based screening study

Authors: Sæmundur Rögnvaldsson, Alessandro Gasparini, Sigrun Thorsteinsdottir, Ingigerdur Sverrisdottir, Elias Eythorsson, Thorir Einarsson Long, Robert Palmason, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni A. Agnarsson, Margret Sigurdardottir, Isleifur Olafsson, Ingunn Thorsteinsdottir, Jon Thorir Oskarsson, Asbjorn Jonsson, Runolfur Palsson, Olafur Skuli Indriðason, Andri Olafsson, Malin Hultcrantz, Brian G. M. Durie, Stephen Harding, Ola Landgren, Thorvardur Jon Love, Sigurdur Yngvi Kristinsson.

Myeloma Paper of the Day, December 26th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.

Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response.

Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.